Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SULGEN Spray Phleum pratense for grass pollen allergy
2011-002301-29Phase 2Active
- Sponsor
- Roxall
- Start
- Jul 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of SULGEN in grass pollen allergy, allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by Roxall. Primary endpoints: Increase in tNPT threshold at final visit and Optimal dose determination. Started Jul 2020; status: active.
02
Drugs
SULGEN
03
Conditions
grass pollen allergyallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2011-002301-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002301-29.